Sentence examples for anchor trial from inspiring English sources

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.

METHODS:The 12-week ANCHOR trial randomized 702 statin-treated patients (73% with DM; 39% women) at increased CVD risk with TG 200-499 mg/despiteite controlled low-density lipoprotein cholesterol (LDL-C; 40-99 mg/dL) to receive icosapent ethyl 2 g/day, 4 g/day, or placebo.

In the ANCHOR trial, ranibizumab was superior to verteporfin for treatment of predominantly classic neovascular AMD (Brown et al. 2006).

At 12 months in the ANCHOR trial, ranibizumab-treated patients showed significant improvements in anatomic outcomes compared with verteporfin PDT-treated patients (Brown et al. 2006).

11, 12 In the ANCHOR trial, 423 patients with predominantly classic CNV due to neovascular AMD were randomized to PDT every 3 months as needed, or monthly intravitreal injection of either 0.3 mg or 0.5 mg ranibizumab.

Furthermore, approximately three-quarters of patients with neovascular macular degeneration have the type of disease studied in MARINA (minimally classic or occult choroidal neovascularization) [ 2, 11], compared with one-quarter of patients who have predominantly classic disease [ 11], which was studied in the ANCHOR trial [ 3].

While we await in vivo clinical trials that compare all-suture anchors to currently used anchors, Barber and Herbert have provided data to inform anchor choice, and using their biomechanical data at time zero from all-suture anchor trials in an animal model, we can determine the anchors' feasibility for human clinical investigations.

50 Most cost-effectiveness studies used data from the MARINA and ANCHOR trials with monthly ranibizumab injections.

Although VA outcomes were similar to those of the MARINA and ANCHOR trials with fewer intravitreal injections, substantial trial design differences limit comparisons.

Ranibizumab treatment in the FOCUS, MARINA, and ANCHOR trials was once monthly injection for 24 months, and this regimen resulted in significant improvements in VA for ranibizumab-treated patients compared with controls (both sham and active).

Data on patient-reported quality of life (QOL) and vision-related function (VRF) from the MARINA and ANCHOR trials are available in abstract form (Chang et al. 2006; Chang et al. 2007; Schwartz et al. 2007; Suner et al. 2007).